Alpa Laboratories Limited (ALPA) fundamentals
Alpa Laboratories Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as ALPA (ISIN INE385I01010). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Alpa Laboratories Limited does
Alpa Laboratories Limited is an India-based global pharmaceutical company engaged in manufacturing and selling finished pharmaceutical dosage forms. Its product range includes a variety of ethical, generic, and over the counter (OTC) drugs in various finished dosage forms for both human and veterinary use. Its human use products include capsules, such as Ampicillin Capsule IP/BP, Amoxycillin Trihydrate Capsule IP/BP, Cloxacillin Capsules IP/BP and Piroxicam Capsules IP BP; creams, gels and ointments, which include Lidocaine Hydrochloride Jelly IP/USP, Nitrofurazone Cream USP, Miconazole Cream IP/BP and Clobetasole Ointment/Cream BP; ear and eye drops, such as Benzylpenicillin Inj. IP/BP and Benzathine Penicillin Inj. IP/BP, and tablets, such as Ciprofloxacin Tablet IP / BP, Paracetamol Tablet IP/BP and Tinidazole Tablets IP/BP. Its veterinary products include boluses, such as Alpamin Bolus, Melovin-P Bolus and Alpazole Bolus, and injections, such as Atropine Inj. B.Vet.C and others.
Valuation and market data
| Last close | ₹61.69 |
|---|---|
| Market capitalisation | ₹129 crore |
| Enterprise value | ₹130 crore |
| P/E (TTM) | 0.00 |
| Price to book | 0.75 |
| Price to sales (TTM) | 1.07 |
| Book value per share | ₹82.11 |
| Dividend yield | 0.00% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Mon Aug 06 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹122 crore | ₹17 crore | ₹15 crore | 0.00 |
| Mar 2025 | ₹136 crore | ₹26 crore | ₹20 crore | 9.42 |
| Mar 2024 | ₹124 crore | ₹21 crore | ₹17 crore | 8.01 |
| Mar 2023 | ₹102 crore | ₹16 crore | ₹13 crore | 5.90 |
| Mar 2022 | ₹123 crore | ₹20 crore | ₹14 crore | 6.71 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 57.2% |
|---|---|
| Foreign institutions (FII) | 0.3% |
| Mutual funds | 0.0% |
| Other domestic institutions | 0.1% |
| Retail and others | 42.4% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.